| First Author | Huang B | Year | 2012 |
| Journal | Oncogene | Volume | 31 |
| Issue | 4 | Pages | 527-34 |
| PubMed ID | 21706051 | Mgi Jnum | J:181071 |
| Mgi Id | MGI:5308707 | Doi | 10.1038/onc.2011.252 |
| Citation | Huang B, et al. (2012) RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 31(4):527-34 |
| abstractText | Transcription factor RUNX3 is inactivated in a number of malignancies, including breast cancer, and is suggested to function as a tumor suppressor. How RUNX3 functions as a tumor suppressor in breast cancer remains undefined. Here, we show that about 20% of female Runx3(+/-) mice spontaneously developed ductal carcinoma at an average age of 14.5 months. Additionally, RUNX3 inhibits the estrogen-dependent proliferation and transformation potential of ERalpha-positive MCF-7 breast cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice. Furthermore, RUNX3 inhibits ERalpha-dependent transactivation by reducing the stability of ERalpha. Consistent with its ability to regulate the levels of ERalpha, expression of RUNX3 inversely correlates with the expression of ERalpha in breast cancer cell lines, human breast cancer tissues and Runx3(+/-) mouse mammary tumors. By destabilizing ERalpha, RUNX3 acts as a novel tumor suppressor in breast cancer. |
